CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing mRNA-based medicines, announced it will present the first clinical data from its Phase 1 CVGBM cancer vaccine study. The presentation is scheduled for the European Society for Medical Oncology (ESMO) Congress in Barcelona from September 13-17, 2024.

According to Dr. Myriam Mendila, Chief Scientific Officer of CureVac, the mRNA technology being assessed has the potential to significantly advance cancer vaccines. The Phase 1 study includes dose-escalation (Part A) and dose-expansion (Part B) parts. Initial data on safety and tolerability at dose levels of 12-100 µg will be shared during the oral presentation.

Prof. Dr. Dr. Ghazaleh Tabatabai will present the first-in-human results on September 13. Preclinical data supporting CVGBM's development will also be shared. CureVac's CVGBM vaccine shows immunogenicity in glioblastoma, featuring mRNA encoding eight epitopes from known tumor-associated antigens.